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ABSTRACT 
Following  a  request  from  the  European  Commission,  the  EFSA  Panel  on  Dietetic  Products,  Nutrition  and 
Allergies (NDA) was asked to deliver a scientific opinion on the safety of a synthetic dihydrocapsiate (DHC) as 
a food ingredient in the context of Regulation (EC) No 258/97 taking into account the comments and objections 
of a scientific nature raised by Member States. Dihydrocapsiate belongs to a group known as  capsinoids which 
have been shown to occur naturally in a number of chilli and sweet peppers. The applicant intends to market 
DHC to food manufacturers as an ingredient for incorporation into foods of various categories at concentration 
levels varying from 8 to 2050 mg per kg. Considering the proposed uses the mean intake of synthetic DHC was 
estimated to be around 12 – 13 mg/day (8.1 mg/day for pre-school children); the 97.5
th percentile intakes of 
adults  and  the  elderly  were  estimated  to  be  around  34  mg/day  (18.5  mg/day  for  pre-school  children). 
Calculations based on body weights resulted in the highest intakes being for pre-school children (mean: 0.6 
mg/kg bw/day; 97.5
th percentile: 1.3 mg/kg bw/day). The applicant has provided a range of toxicological studies 
with DHC. The Panel concludes that it has no safety concerns regarding genotoxicity. Studies on developmental 
toxicity in rats and rabbits using commercial grade DHC did not show adverse effects on pregnant animals or on 
foetal growth and development. The no-observed adverse effect level (NOAEL) of three subchronic oral toxicity 
studies in rats was consistently at 300 mg DHC/kg bw/day. The Panel is of the opinion that the margin of safety 
(MOS) in relation to the NOAEL of 300 mg/kg bw/day is sufficient, including the highest estimated intake of 1.3 
mg/kg bw/day for preschool children. The Panel concludes that the novel food ingredient, DHC, is safe under the 
proposed uses and use levels. 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on the safety of „dihydrocapsiate 
(DHC)‟ as a food ingredient in the context of Regulation (EC) No 258/97 taking into account the 
comments and objections of a scientific nature raised by Member States.  
Dihydrocapsiate belongs to a group known as capsinoids. They were first identified in the fruits of a 
non-pungent cultivar of pepper (Capsicum annuum L.) and have been shown to occure naturally in a 
number of chilli and sweet peppers. In contrast to the analogous capsaicinoids (with capsaicin as 
major representative), the vanilloid and the fatty acid moieties in the capsinoids are bound via an 
ester rather than an amide bond. The applicant developed a procedure enabling the production of 
synthetic  DHC  which  is  based  on  a  lipase-catalysed  esterification  of  vanillyl  alcohol  and  8-
methylnonanoic acid. Batch testing confirmed that the product complies with the given specifications. 
The applicant provided sufficient information regarding the specification, manufacture, composition 
and stability of DHC. 
The applicant intends to market DHC to food manufacturers as an ingredient for incorporation into a 
range of foods such as baked goods, beverages, confectionery, cereals and desserts, and other foods 
including ready-to-eat frozen meals, soup, sweeteners and salad dressings. The applicants intends 
DHC use levels of about 8 - 18 mg per kg in beverages, 20 - 40 mg in cereals and desserts, and 11 mg 
per kg in ready-to-eat frozen meals and soups; higher concentration levels are intended for chocolates 
(75  mg/kg),  baked  goods  (100  mg/kg),  salad  dressings  (164  mg/kg)  hard  candies  (270  mg/kg), 
whitener/creamer (383 mg/kg), sugar-free gum (1134 mg/kg), sweeteners (2050 mg/kg). Based on 
these proposed uses and use levels, the applicant conducted an intake estimation based on individual 
consumption data collected in the United Kingdom. The mean intake of DHC was around 12 - 13 
mg/day  for  school  children,  adults  and  the  elderly,  and  8.1  mg/day  for  pre-school  children, 
respectively; the 97.5th percentile intakes of adults and the elderly were around 34 mg/day  and 18.5 
mg/day for pre-school children, respectively. Calculations based on body weights resulted in the 
highest intakes being for pre-school children (mean: 0.6 mg/kg bw/day; 97.5th percentile: 1.3 mg/kg 
bw/day).  
The  available  data  on  absorption,  distribution,  metabolism  and  excretion  (ADME)  suggest  that 
ingested DHC is rapidly metabolised in the gut of rats and humans to form vanillyl alcohol, vanillic 
acid and 8-methylnonanoic acid. After absorption, the first two are converted into glucuronide and/or 
sulphate conjugates in the liver and eliminated predominantly by the kidneys into the urine. Total 
excretion in the urine, faeces and expired air after 72 hr was 98.0 %. The methyl-branched fatty acid 
8-methylnonanoic acid is likely to be subject to a degradation via ß-oxidation. Terminal ω-oxidation 
might constitute an alternative pathway.  
The applicant has provided a range of toxicological studies with DHC including in vitro and in vivo 
genotoxicity studies. Based on the results of these studies and in the absence of structural alerts for 
genotoxicity, the Panel concludes that it has no safety concerns regarding genotoxicity. Studies on 
developmental toxicity in rats and rabbits using commercial grade DHC did not show adverse effects 
on pregnant animals or on foetal growth and development up to the highest dose administered (1000 
mg/kg bw/day). In a 13-week oral toxicity study in rats with laboratory scale DHC several changes 
were observed at the highest dose level (1000 mg/kg bw/day) which indicate an effect on the liver. 
Administration of commercial grade DHC to rats for 13 weeks at the same dose level induced in part 
the  same  specific  changes  indicating  an  effect  on  the  liver. In addition, commercial grade DHC 
induced additional changes indicative of an effect on the kidneys. No explanation for the observed 
differences could be provided by the applicant. The Panel concludes that the intermediate dose of 300 
mg DHC/kg bw/day is the no-observed adverse effect level (NOAEL) in these 13-week studies. In a 
26-week oral toxicity study, commercial grade DHC induced, at the highest dose level (1000 mg/kg Safety of dihydrocapsiate 
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bw/day), similar changes regarding liver- and kidney-specific parameters as those observed in the 13-
week study with commercial grade DHC. Furthermore, slightly higher incidences of histopathological 
changes in the liver and kidneys compared with the controls were identified in the high-dose group. 
Not all effects induced by the test material were reversed at the end of a 4-week recovery period. The 
Panel concludes that 300 mg DHC/kg bw/day is the NOAEL in this study. 
Taking into account the estimated intake levels resulting from the uses as proposed by the applicant, 
the Panel is of the opinion that the margin of safety (MOS) in relation to the NOAEL of 300 mg/kg 
bw/day in the 26-week rat toxicity study is sufficient, including the highest estimated intake of 1.3 
mg/kg bw/day for preschool children.   
The Panel concludes that the novel food ingredient, DHC, is safe under the proposed uses and use 
levels.Safety of dihydrocapsiate 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On  31  August  2010,  the  company  Toxico-Logical  Consulting  Ltd  on  behalf  of  the  company 
Ajinomoto Co. Inc. submitted a request under Article 4 of the Novel Food Regulation (EC) No 258/97 
to place on the market 'Dihydrocapsiate' (DHC) as a novel food ingredient.  
On 10 March 2011, the competent authorities of the United Kingdom forwarded to the Commission 
their initial assessment report, which came to the conclusion that the DHC meets the criteria for 
acceptance as a novel food. 
On 13 April 2011, the Commission forwarded the initial assessment report to the other Member 
States. Several of the Member States submitted comments or raised objections.  
In consequence, a Community Decision is now required under Article 7, paragraph of Regulation 
(EC) No 258/97. 
The concerns of a scientific nature raised by the Member States can be summarised as follows: 
  There is a contradiction in the specification data provided by the applicant who indicated that the 
MNA content in the end product may vary between 2 to 7 % and that the DHC content was of > 
94 %.  
  Stability tests on the novel ingredient were carried out at temperature between 5°C and - 20°C, 
but not at higher temperatures and not in products to which the ingredient is intended to be added. 
  The level of details for the exposure assessment is insufficient.  
  Consumption of one intended DHC portion provides a 25 times higher intake than average intake 
from natural foods, in the worst case scenario it could be up to 280 times higher. 
  Ambiguous  results  from  genotoxicity  testing:  positive  results  in  an  AMES  test  (Salmonella 
tiphymurium, TA100 strain) and chromosome aberration test with CHL fibroblasts, both without 
a metabolising system (S9-mix) and “equivocal” results in the comet assay versus negative results 
in two in vivo tests in rats and mice. However, the later two were not carried out under GLP 
conditions. 
  It is unlikely that DHC is able to accumulate in the body and target TRPV-1 (transient receptor 
potential vanilloid subfamily member 1) receptors other than those located along the digestive 
tract.  However,  TRPV-1  receptors  are  activated  by  different  stimuli,  including  derivatives 
belonging to the family of vanilloids. It is not possible, based on the available data, to determine 
whether these receptors are likely to be stimulated by the DHC metabolites at the doses envisaged 
by the applicant. Moreover, no neurotoxicity study has been carried out. 
  Lack of data on the capacity of human cells for beta-oxidising 8-methyl nonanoic acid (MNA). 
MNA  is  a  methylated  nonanoic  short-chain  fatty  acid,  branched  and  with  an  odd  number  of 
carbons in the carbon chain. This type of fatty acid is not synthesised by the human body. Their 
synthesis is of bacterial origin. They are therefore likely to be present only at trace levels in 
fermented products or in animal products from ruminants (metabolism by the rumen bacteria).  It 
is unclear whether human cells are capable of beta-oxidising the MNA, in particular where a large 
quantity is to be metabolised. 
  Inadequate design of human studies, i.e. short duration, low dose and small number of subjects.  
  Absence of a study in children, in whom the doses likely to be ingested are twice as high per kg 
body weight as in adults. Safety of dihydrocapsiate 
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TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Food Safety 
Authority  is  asked  to  carry  out  the  additional  assessment  for  „Dihydrocapsiate‟  as  a  novel  food 
ingredient in the context of Regulation (EC) N° 258/97. 
EFSA is asked to carry out the additional assessment and to consider the elements of a scientific 
nature in the comments raised by the Member States. 
 Safety of dihydrocapsiate 
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ASSESSMENT 
In  accordance  with  Commission  Recommendation  97/618/EC,  the  novel  food  ingredient 
„Dihydrocapsiate  (DHC)‟  is  allocated  to  Class  1.2,  i.e.  foods  or  food  ingredients  that  are  „pure 
chemicals or simple mixtures which are not obtained from plants, animals or microorganisms that 
have been genetically modified. The source of the NF has no history of food use in the Community‟. 
Accordingly,  information  related  to  the  structured  schemes  I,  II,  III,  IX,  XI,  XII  and  XIII  of 
Commission Recommendation 97/618/EC has been submitted.  In the text, these structured schemes 
are listed 1 to 7. The assessment is based on data supplied in the original application, the initial 
assessment by the competent authority of The United Kingdom, the concerns and objections of the 
other Member States and the responses of the applicant. It is noted that the novel food ingredient is 
intended by the applicant to be added to foods to enhance energy expenditure and fat oxidation, and 
for its sensory effects. This assessment concerns only risk that might be associated with consumption, 
and is not an assessment of DHC with regard to any claimed benefit. 
 
1.  SPECIFICATION OF THE NOVEL FOOD (NF) 
The structure of dihydrocapsiate (4-hydroxy-3-methoxybenzyl 8-methylnonanoate;  С18Н28O4; CAS-
no: 205687-03-2) is shown in Figure 1.  
 
H3CO
O H
O
C
O
 
 
Figure 1: Structure of dihydrocapsiate 
 
Dihydrocapsiate  and  the  structurally-related  capsiate  (4-hydroxy-3-methoxybenzyl  (E)-8-methyl-6-
nonenoate)  and  nordihydrocapsiate  (4-hydroxy-3-methoxybenzyl  7-methyloctanoate)  belong  to  a 
group known as capsinoids. They were first identified in the fruits of a non-pungent cultivar of pepper 
(Capsicum  annuum  L.)  (Yazawa  et  al.,  1989;  Kobota  et  al.,  1998).  Dihydrocapsiate  and  other 
capsinoids occur naturally in chilli and sweet peppers. In contrast to the analogous capsaicinoids, the 
vanilloid and the fatty acid moieties in the capsinoids are bound via an ester rather than an amide 
bond.  
The applicant has developed a procedure enabling the production of synthetic DHC which is based on 
a lipase-cataylsed esterification of vanillyl alcohol and 8-methylnonanoic acid.  
Specifications  provided  by  the  applicant  are  shown  in  Table  1.  They  comprise  physico-chemical 
parameters of the novel food ingredient, a minimum assay value for DHC, and maximum contents of 
the employed starting materials. Taking into account the production procedure (see Section 2), the 
maximum contents of synthesis-related substances, of the solvent used for extraction and of heavy 
metal contaminants have also been specified.  
 
According to the applicant, a residual amount of up to 6 % 8-methylnonanoic acid is retained in the 
final  product;  the  resulting  low  pH  prevents  the  dissociation  of  the  phenolic  moiety,  and  thus 
contributes to the stabilisation of the molecule. 
 Safety of dihydrocapsiate 
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The applicant provided compositional data for seven batches (between 10 and 20 kg each lot) of the 
novel food ingredient produced sequentially on pilot plant scale over a period of 3 months in 2006 
(Table 2).  
 
The analyses were conducted by two external accredited analytical laboratories which operated either 
in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP), or in 
compliance with ISO/IEC 17025. 
 
Table 1:   Specifications for the novel food ingredient DHC as proposed by the applicant 
Test item  Acceptance criteria  Method
a 
Description  Viscous, colourless to yellow liquid  JSFA VII 
Identification (Infrared spectrum ) 
 
Absorption at wave numbers 2953, 2928, 
2855, 1733, 1519, 1278, 1241, 1036, 818 
and 798 cm-1 
FCC V 
Specific gravity  1.02 – 1.03  FCC V 
Dihydrocapsiate (DHC)  ≥ 94 %  HPLC-UV
b 
Starting materials     
      8-Methylnonanoic acid  2 – 7 %  HPLC-UV
b 
      Vanillyl alcohol  < 1 %   
Synthesis-related substances
c  < 2 %  HPLC-UV
b 
Magnesium  < 1 ppm  JSFA VII 
Copper  < 1 ppm  JSFA VII 
Arsenic  < 1 ppm  JP XIV 
Cadmium  < 1 ppm  FCC V 
Lead  < 1 ppm  FCC V 
Hexane  < 5 ppm  GC-FID
b 
a  FCC V: Food Chemicals Codex Fifth Edition;  JSFA VII: The Japan„s Specifications and Standards for Food Additives      
Seventh Edition ; JP XIV: The Japanese Pharmacopoeia Fourteenth Edition  
b  analytical details of the methods have been provided 
c  vanillyl 6-bromohexanoate; (4-hydroxy-3-methoxybenzyl) 6-bromohexanoate 
  vanillyl decanoate; (4-hydroxy-3-methoxybenzyl) decanoate 
  vanillyl dihydrocapsiate; [4-(4-hydroxy-3-methoxybenzyloxy)-3-methoxybenzyl] 8-methylnonanoate 
  diacyl form; [4-(8-methylnonanoyl)-3-methoxybenzyl] 8-methylnonanoate 
 
Table 2:   Compositional data on seven lots of the novel food ingredient DHC  produced  at  pilot 
  plant scale in the period from June to August 2006 
  Lot 
060626 
Lot 
060705 
Lot 
060712 
Lot 
060720 
Lot 
060731 
Lot 
060807 
Lot 
060817 
Dihydrocapsiate (%)  95.0  95.7  94.2  94.1  93.5  94.0  94.6 
Starting materials               
   8-Methylnonanoic acid (%)  2.0  2.0  3.3  3.4  5.8  4.3  4.8 
   Vanillyl alcohol (%)  0.04  0.03  0.03  0.03  < 0.025  < 0.025  < 0.025 
Synthesis-related substances (%)  1.10  0.86  0.74  0.69  0.81  1.39  0.75 
   Vanillyl 6-bromohexanoate (%)  0.07  0.07  n.d.
a  n.d.  n.d.  0.07  < 0.025 
   Vanillyl decanoate (%)  0.04  0.04  0.04  0.04  0.04  0.04  0.03 
   Vanillyl dihydrocapsiate (%)  0.60  0.50  0.48  0.47  0.48  0.73  0.37 
   Diacyl form (%)  0.14  0.12  0.11  0.09  0.17  0.42  0.24 
   Others (%)  0.25  0.13  0.11  0.09  0.12  0.13  0.085 
Mass balance (% w/w)   98.14     98.59    98.27    98.22  100.11   99.69  100.15 
Magnesium (mg/kg)     0.3  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2 
Copper (mg/kg)  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2 
                                                       
a not detected  Safety of dihydrocapsiate 
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Arsenic (mg/kg)  < 1.0  < 1.0  < 1.0  < 1.0  < 1.0  < 1.0  < 1.0 
Cadmium (mg/kg)  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2 
Lead (mg/kg)  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2  < 0.2 
Hexane (mg/kg)  < 5  < 5  < 5  < 5  < 5  < 5  < 5 
Specific gravity (g/ml)  1.030  1.030  1.028  1.028  1.024  1.026  1.025 
 
The Panel considers the compositional data provided for the novel food ingredient as sufficient. 
Data on stability 
According to the applicant, the novel food ingredient is typically stored at -20°C in 1 kg amounts in 
aluminium pouches held in sealed containers. Data were provided on the stability upon storage at 
temperatures of -20°C, 5°C and 25°C up to 24 months (Table 3).  
Table 3:   Stability  of  the  novel  food  ingredient  (Lot  NO:  070813)  upon  storage  at  different 
  temperatures 
                                                                                            Months 
  0  6  12  24 
                                                                              storage at -20°C ± 5°C 
Dihydrocapsiate (%)  95.7  95.7  94.6  95.1 
Vanillyl alcohol (%)  0.12  0.12  0.11  0.11 
8-Methylnonanoic acid (%)  3.9  3.9  3.9  4.0 
Other synthesis-related substances (%)  0.59  0.59  0.57  0.66 
                                                                              storage at  5°C ± 3°C                
Dihydrocapsiate (%)  95.4  95.2  94.7  94.3 
Vanillyl alcohol (%)  0.11  0.34  0.37  0.58 
8-Methylnonanoic acid (%)  3.9  4.1  4.2  4.5 
Other synthesis-related substances (%)  0.71  0.62  0.63  0.70 
                                                                               storage at 25°C ± 2°C
a 
Dihydrocapsiate (%)  96.8  95.5  95.6  95.3 
Vanillyl alcohol (%)  0.03  0.31  0.36  0.47 
8-Methylnonanoic acid (%)  2.0  2.4  2.5  2.8 
Other synthesis-related substances (%)  1.25  1.37  1.50  1.74 
a  relative humidity: 60 % ± 5 % 
 
The applicant also checked the stability of DHC in a beverage subjected to a heating procedure of 
80°C for 20 minutes. The test beverage contained high fructose corn syrup, citric acid, sodium citrate, 
sodium  chloride,  monopotassium  phosphate,  aspartame,  acesulfam  potassium,  and  liquid  flavour 
(natural orange extract); the pH was 3.4. Dihydrocapsiate (0.5 %) was incorporated into the beverage 
via  an  emulsifying  formulation.  After  the  thermal  treatment  more  than  95  %  of  the added  DHC 
remained.  
In response to Member States´ comments regarding the stability of the novel food ingredient in foods 
that will be heated prior to use, the applicant checked the stability of DHC upon heating for up to 30 
minutes at temperatures of up to 200°C. As shown in Table 4, the novel food ingredient exhibited 
sufficient stability up to 150°C; treatments at 200°C resulted in significant degradation.  
According to the applicant, DHC could be sprayed onto baked foods, for example biscuits, after the 
baking step in order to avoid temperatures of more than 150°C, and to maintain its stability and 
sensorial properties. 
Table 4:   Recovery of DHC upon heating of the novel food ingredient for up to 30 min. at  200°C   
 Heating temperature                                                     Heating time (min) 
  0  10  20  30 Safety of dihydrocapsiate 
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                                                                              dihydrocapsiate (%) 
80°C  100  100.1  99.4  99.7 
100°C  100  99.9  99.4  98.8 
120°C  100  99.1  99.1  98.5 
150°C  100  98.7  97.7  96.2 
200°C  100  75.5  65.8  55.3 
 
The Panel considers that the data provided sufficient information to demonstrate the stability of the 
novel food ingredient at a temperature of 25°C for up to 24 months. The Panel also noted that DHC is 
stable at temperatures of up to 150°C for 30 minutes.  
2.  EFFECT OF THE PRODUCTION PROCESS APPLIED TO THE NF 
The  synthesis  of  DHC  is  based  on  an  enzyme-catalyzed  esterification  of  vanillyl  alcohol  and  8-
methylnonanoic acid.  
The  starting  material,  8-methylnonanoic  acid,  is  prepared  from  isobutyl  bromide  and  6-
bromohexanoic  acid  ethyl  ester  through  a  Grignard  coupling  reaction  and  de-protection  process. 
According to a certificate of analysis provided by a manufacturer, the purity (gas chromatography) of 
the material was ≥ 99.0 %. Vanillyl alcohol is obtained by reduction of vanillin. According to the 
certificate of analysis provided by a manufacturer, the mininum assay was 98.8 %. 
8-Methylnonanoic acid is esterified with vanillyl alcohol (V-OH) using a lipase (Novozym
® 435 FG, 
recently  renamed  Lipozyme  435;  produced  by  Novozymes  Denmark)  as  catalyst.  A  certificate  
including an approval reference of the Danish Veterinary and Food Administration was provided.   
The enzyme is employed in immobilised form on an inert methacrylate carrier. According to studies 
performed by the enzyme producer, there is no release of protein or other materials from the carrier 
material  under  normal  use.  As  further reassurance, the applicant implemented three post-reaction 
filtration steps in the production process, using filters of 5 µm porosity. The size of the Novozym
® 
435 FG granulate product is approximately 500 µm (range 150 – 190 µm); thus the filtration steps are 
considered to eliminate any granulate from the final product. Actual analytical data regarding the 
absence of protein residues have not been provided. 
Following  the  esterification,  n-hexane  is  employed  to  quench  the  reaction,  as  well  as  for  the 
subsequent  extraction step. 
The reaction vessels are made of high grade stainless steel typical of pharmaceutical and food grade 
standard manufacturing plants. The scale-up to commercial scale is not considered to impact the 
quality of the resulting DHC or its ability to comply with the specification of the resulting commercial 
grade DHC food ingredient. 
The Panel concludes that the production process is sufficiently described by the applicant and does 
not raise concerns. 
3.  HISTORY OF THE ORGANISM USED AS A SOURCE  
Not applicable. Safety of dihydrocapsiate 
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4.  ANTICIPATED INTAKE/EXTENT OF USE OF THE NF 
The applicant intends to market DHC to food manufacturers as an ingredient for incorporation into a 
range of foods such as baked goods, beverages, confectionery, cereals and desserts and other foods 
including ready-to-eat frozen meals, soup, sweeteners and salad dressings (Table 5). The proposed use 
levels have been calculated so that each portion of a given food will contain 3 mg of DHC. In the 
absence  of  a  standard list of portion sizes,  average quantities consumed per serving occasion by 
adults,  according  to  data  from  the  UK  National  Diet  and  Nutrition  Survey  (NDNS)  (Office  for 
National Statistics, 2005) have been used as the basis for the calculations (Table 5).  
The Panel notes that the food categories of interest include those which could be consumed by pre-
school children as well as school children, adults and the elderly. 
Table 5:   Intended uses and use levels of DHC 
Food Category   Average 
portion size (g)* 
Use level to provide 3 
mg per serving (mg/kg) 
  
Baked goods 
   Cereal bars   33  90.1   
   Biscuits & cookies   33  90.5   
   Crackers   32  94.7   
   Rice-based snacks   25  119.0   
Beverages 
   Dilutable drinks   250  12.0   
   Carbonated drinks   267  11.2   
   Energy drinks   368  8.1   
   Fruit juice-based drinks   241  12.5   
   Drink mixes   209  14.3   
   Coffee-based drinks   212  14.1   
   Meal replacement drinks   320  9.4   
   Flavoured water - still   285  10.5   
   Tea-based drinks   208  14.4   
   Vegetable juice   169  17.8   
Confectionery 
   Sugar-free gum   3  1133.9   
   Hard candy   11  269.8   
   Chocolate confectionery   40  74.8   
Cereals and desserts 
   Frozen ices   86  34.8   
   Frozen dairy desserts   82  36.5   
   Pudding mixes   140  21.4   
   Yogurt (not fruit)   117  25.7   
   Yogurt (fruit-flavoured)   142  21.2   Safety of dihydrocapsiate 
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   Instant oatmeal cereal   123  24.4   
   Other cereals   71  42.2   
Other foods  
   Ready-to eat frozen meals   276  10.9   
   Soup   280  10.7   
   Whitener/creamer   8  382.8   
   Replacement meal   265  11.3   
   Vegetable protein   61  49.5   
   Salad dressing   18  164.3   
   Sweeteners   1  2049.6   
 
* Average quantity consumed per serving occasion, based on UK NDNS data for adults (Office for National Statistics, 2005). 
 
Based on these proposed uses and use levels, the applicant conducted an intake estimation based on 
individual consumption data collected by UK NDNS surveys (Office for National Statistics, 2005; 
UKDA, 1995, 2001). The mean estimated intake of DHC was around 12 – 13 mg/day (8.1 mg/day for 
pre-school children); the 97.5
th percentile intakes of adults and the elderly were around 34 mg/day 
(18.5 mg/day for pre-school children). Calculations based on body weights resulted in the highest 
intakes being for pre-school children (mean: 0.6 mg/kg bw/day; 97.5
th percentile: 1.3 mg/kg bw/day).  
Table 6:   Estimated intakes* based on use levels providing 3 mg of DHC in an average portion for 
  adults  
DHC intake, mg/day  DHC intake, mg/kg bw/day 
Age group   Mean   P90   P95   P97.5   Mean   P90   P95   P97.5  
Adults   12.3   23.3   29.5   33.8   0.2   0.3   0.4   0.4  
Pre-school 
children  
8.1   13.1   15.7   18.5   0.6   0.9   1.1   1.3  
School 
children  
12.8   19.9   23.2   26.2   0.4   0.7   0.8   0.9  
Elderly   11.7   23.2   29.2   34.2   0.2   0.3   0.4   0.5  
* For consumers only 
 
5.  INFORMATION FROM PREVIOUS EXPOSURE TO THE NF OR ITS SOURCE   
5.1.   Natural occurrence in the human diet 
Dihydrocapsiate  is  part  of  the  human  diet  as  it  is  naturally  present  in  peppers.  It  has  first  been 
identified in the fruits of a non-pungent cultivar, CH-19 Sweet, of pepper (Capsicum annuum L.) 
(Yazawa et al., 1989; Kobata et al., 1998).  Capsinoids have been shown to occur naturally in most 
chilli peppers (Capsicum annuum, Capsicum frutescens, Capsicum chinense, Capsicum baccatum, 
Capsicum  pubescens)  and  sweet  peppers  like  paprika  (Capsicum  annuum  var.  annuum  L.).  The 
contents of DHC and capsiate have been determined in various Capsicum species (Singh et al., 2009). 
According to the applicant, the average concentration of DHC in the analysed Capsicum samples 
(n = 77) was 19 mg/kg; the 90
th, 95
th and 97.5
th percentiles were 43, 48 and 68 mg/kg, respectively. Safety of dihydrocapsiate 
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Capsicum fruits and peppers have a long history of human consumption. Chillies are among the oldest 
cultivated  crops  of  South  and  Central-America.  The  wild  Capsicum  annuum  var.  aviculare  is 
harvested  and  sold  in  the  marketplace  alongside  the  larger-fruited  domesticated  chillies.  Sweet 
peppers  are  widely  consumed  and  cultivated  in  Hungary  and  Bulgaria  and  in  the  Mediterranean  
countries  Spain,  France  and  Italy.  They  are  also  widely  grown  and  consumed  in  North  Africa, 
California and New Mexico, as well as in the tropics and the Caribbean.  
Based on FAO Food Balance Sheet data for capsicum from 2004 and 2005 for 157 countries, the 
applicant estimated that DHC intakes could range from 0 in countries where capsicums do not form 
part of the diet up to 5 to 16 mg/day (0.07 – 0.27 mg/kg bw/day) in some European countries such as 
Bosnia  and  Herzegovina  and  Hungary  where  capsicums  are  consumed  in  larger  quantities.  DHC 
intakes have been calculated for average consumers assuming average capsicum consumption and 
average levels of DHC (19 mg/kg). 
For the United Kingdom, the applicant estimated based on NDNS consumption data of peppers for 
adults that the typical daily intake of DHC of  natural occurance ranges from approximately 0.01 to 
0.06 mg/kg bw/day. 
Vanillyl alcohol is being used as a flavouring substance in the EU. It was evaluated by JECFA at its 
57
th meeting (JECFA, 2002).  The EFSA Scientific Panel on Food Additives, Flavourings, Processing 
Aids and Materials in Contact with Food (AFC) agreed with this evaluation and considered vanillyl 
alcohol not to be of safety concern at the estimated level of intake as a flavouring substance (EFSA, 
2008). 
5.2.  Previous exposure of DHC via food supplements 
Dihydrocapsiate has been determined to be generally regarded as safe (GRAS) at 1 and 3 mg per 
serving in the United States of America (USA), and these determinations were reviewed by the US 
Food and Drug Administration who provided “no objection” Agency response letters in 2009 and 
2010. A chilli pepper extract, known as CH-19 Sweet extract, contains capsinoids of which DHC 
represents approximately 20 %. This extract is sold as a food supplement in the USA and Japan. The 
Panel notes that the applicant has not provided consumption data. 
6.  NUTRITIONAL INFORMATION ON THE NF 
Dihydrocapsiate manufactured by the applicant is identical to the DHC found as a component of the 
capsinoids contained in Capsicums. The Panel considers that both synthetically produced DHC and 
DHC naturally occurring in the diet do not have a nutritionally relevant role in the human diet, and 
that the consumption of the novel food ingredient is not nutritionally disadvantageous. 
7.  MICROBIOLOGICAL INFORMATION ON THE NF 
According to the information provided by the applicant,  DHC is produced by chemical synthesis 
under GMP with good hygienic practices, and stored using tightly sealed heavy-duty bags made of 
Polyethylene Terephthalate/Aluminum foil/Oriented nylon/Liner Low Density polyethylene at -20ºC; 
the possibility of any significant microbiological contamination during either production or storage is 
considered remote.  
For four of the batches of the novel food ingredient produced at pilot scale (Table 2), the total aerobic 
count was < 3000 Colony Forming Units (CFU)/g, and the counts for yeast/mould were < 100 CFU/g. 
No E. coli was detected in any of the four batches investigated. The test was conducted according to 
the method of Specifications and Standards for Foods, Food Additives, Food Additives General Tests Safety of dihydrocapsiate 
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“Microbial Limit Test” (Notification No. 370, 1959), Ministry of Health and Welfare of Japan. The 
data provided do not raise concerns with regards to a microbial risk. 
8.  TOXICOLOGICAL INFORMATION ON THE NF 
The applicant has carried out a number of in vitro and animal studies which have been also published 
in scientific literature. Some were carried out using synthetic DHC produced on a commercial scale 
by the applicant, some using laboratory-scale DHC. In addition, the applicant has provided studies 
with sweet pepper extract (CH-19 Sweet). Except for a pharmacokinetic study these examinations 
were not considered relevant for the safety assessment since the material tested cannot be regarded as 
representative  for  the  product  intended  to  be  marketed  (sweet  pepper  extract  contains  7-9  % 
capsinoids of which only 20 % is DHC).    
The  toxicological  data  comprise  pharmacokinetic  studies,  genotoxicity  studies  (tests  for  gene 
mutations in bacteria; tests for chromosomal aberrations in chinese hamster cells; micronucleus tests 
in mice, gene mutation tests using transgenic rats and comet assay in rats), a single dose oral toxicity 
study in mice, repeated dose oral toxicity tests with DHC administered to rats for 13 and 26 weeks, 
and studies on developmental toxicity in rats and rabbits.  
8.1.  Absorption, distribution, metabolism and excretion (ADME) data 
The  applicant  provided  a  pharmacokinetic  study  using 
14C-DHC  labelled  at  the  vanillic  alcohol 
moiety, which was carried out in male rats (Nemoto, 2005; Bernard et al., 2010). In this study, groups 
of two or three animals received the test material diluted in medium chain triglycerides (MCT) by 
gavage at a single dose of 10 mg/kg bw. Radioactivity was determined in plasma, urine, bile, faeces 
and expired air, carcass as well as specific organs and tissues. In addition, the metabolite profile in 
plasma was analysed by HPLC. 
After  a  single  oral  administration  of 
14C-DHC  to  rats,  the  radioactivity  concentration  in  plasma 
reached a maximum (Cmax 1870 ng eq./mL) at 0.67 hr (tmax) and then declined with an apparent half-
life of 2.4 hr (t1/2). The AUC (0-8 hr) and AUC (0-∞) were 6745 and 7581 ng eq. hr/mL, respectively. 
Total excretion in the urine, faeces and expired air was 94.1 % and 98.0 % up to 24 and 72 hr, 
respectively. Excretion was highest in the urine, i.e. 27.5 %, 57.9 %, 75.1 % and 78.2 % of the dose 
up to 4, 8, 24 and 72 hr after administration, respectively. Excretion in the faeces and expired air was 
19.4 % and 0.5 % of the dose up to 72 hr, respectively. Residual radioactivity in the carcass after 72 
hr was 4.0 % of the dose. When measured at 15 and 30 min after administration, radioactivity was 
highest in the kidneys, followed by the stomach and small intestine, the liver, plasma and blood. At 2 
hr radioactivity was again highest in the kidneys followed by the caecum, stomach and small intestine, 
plasma,  blood,  liver  and  large  intestine.  At  6  hr  the  concentration  of  radioactivity  in  the  tissues 
showed  a  marked  decrease  except  for  the  stomach,  large  intestine  and  caecum.  At  24  hr  after 
administration the concentrations had decreased considerably in all organs. No residual radioactivity 
was detected in the brain. 
In the HPLC analysis of plasma (samples from 15 and 30 min, 2 and 6 hr after administration) no 
DHC was detected but six metabolites designated RP1 – RP6 were identified.  The main metabolites 
at all time points were RP2 (23.8 %, 28.3 %, 15.5 %, 21.4 % of the radioactivity) and RP3 (46.4 %, 
49.4 %, 56.8 %, 20.8 %). The other metabolites were RP4 (detected at all time points; 2.4 - 3.8 %), 
RP1 (at 30 min, 2 and 6 hr; 1.8 – 4.0 %), RP5 and RP6 (detected at 6 hr; approximately 2.6 %). HPLC 
data  obtained  after  treatment  with  ß-glucuronidase/arylsulfatase  and  the  use  of  a ß-glucuronidase 
inhibitor  suggested  that  RP2  is  a  glucuronide  conjugate  of  vanillyl  alcohol,  RP3  is  a  sulphate 
conjugate of vanilyl alcohol and RP4 is a sulphate conjugate of vanillic acid. These data suggest that 
ingested DHC is metabolised in the gut to form vanillyl alcohol, vanillic acid and 8-methylnonanoic Safety of dihydrocapsiate 
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acid.  Vanillyl  alcohol  and  vanillic  acid  are  converted  in  the  liver  into  glucuronide  and  sulphate 
conjugates, and eliminated predominantly by the kidneys into the urine.  
The  Panel  considers  that  8-methylnonanoic  acid  may  be  subject  to  degradation  via  ß-oxidation; 
however, there are no experimental data available on the human capacity to metabolise this methyl-
branched fatty acid. Terminal ω-oxidation might constitute an alternative pathway, resulting in polar 
metabolites that can be excreted as conjugates (Wanders et al., 2010).  
The applicant has also provided the results of pharmacokinetic studies in male rats using a sweet 
pepper extract (CH-19 Sweet) containing 7.5 % capsinoids (DHC, capsiate, nordihydrocapsiate), 20% 
of which are DHC (Shirai et al., 2010a, b). Sweet pepper extract was administered by gavage to fasted 
animals at a single dose of 10 or 100 mg/kg bw. Blood samples were obtained from the portal vein 
and  aorta  at  5,  15  and  30  minutes  and  1,  2  and  4  hours  after  administration  and  analysed  for 
capsinoids using Liquid Chromatography Tandem Mass Spectroscopy (LC-MS/MS) and for vanillyl 
alcohol using HPLC. The plasma levels of capsinoids were below the limit of quantification at all 
time points examined (LOQ 50 ng/ml for each of the capsinoids). Vanillyl alcohol (V-OH) – the 
metabolite common to the three capsinoids – was barely detectable in plasma (only at 5 minutes after 
administration).  In  portal  vein  plasma  V-OH  reached  maximum  concentrations  30  min  after 
administration  (Cmax  0.16  and  1.48  µg/mL  after  administration  of  10  and  100  mg  extract/kg  bw, 
respectively).  Significant  levels  of  sulfate  and  glucuronide  conjugates  of  V-OH  were  detected  in 
plasma from the aorta. These results further support the conclusions of the previous study that orally 
administered  DHC  is  rapidly  hydrolysed  in  the  gastrointestinal  tract.  The  metabolite  V-OH  is 
absorbed and converted in the liver to sulphate and glucuronide conjugates before entering the post-
hepatic systemic blood.  
In a human study, groups of 8 apparently healthy male subjects received a single oral dose of sweet 
pepper extract (CH-19 Sweet) containing 15 or 30 mg of capsinoids, corresponding to 4 and 8 mg 
DHC, respectively (Nakamura, 2006; Bernard et al., 2008a). The respective control groups (n = 4) 
received a placebo. Blood samples were taken at 15 and 30 minutes, 1, 2, 4, 8 and 24 hours after 
administration. The levels of capsinoids and V-OH in blood plasma were below the lower limit of 
quantification at all time points (LLOQ 10 and 50 ng/mL, respectively). These results suggest that 
also in humans capsinoids are rapidly hydrolysed in the gastrointestinal tract and further metabolised. 
The potential effects of capsinoids, i.e. DHC, capsiate and nordihydrocapsiate, and of the capsaicinoid 
capsaicin,  on  the  major  human  drug  metabolising  isozyme  CYP3A4  were  examined  in  vitro 
(Takahashi, 2005; Takanohashi et al., 2010). There was no inhibition of CYP3A4 by DHC and the 
other two capsinoids (<100 µmol/L) whereas capsaicin was clearly shown to inhibit this enzyme (50 
% of the activity was lost at 21.5 µmol/L).   
In summary, the available data suggest that ingested DHC is rapidly metabolised in the gut of rats and 
humans to form vanillyl alcohol, vanillic acid and 8-methylnonanoic acid. After absorption the first 
two  are  converted  into  glucuronide  and/or  sulphate  conjugates  in  the  liver  and  eliminated 
predominantly by the kidneys into the urine. Total excretion in the urine, faeces and expired air after 
72 hr was 98.0 %. The methyl-branched fatty acid 8-methylnonanoic acid is likely to be subject to 
degradation  via  ß-oxidation.  Terminal  ω-oxidation  might  constitute  an  alternative  pathway.  The 
available animal and human data show that the potential risk of DHC accumulation in the fatty tissue 
or the brain can be considered negligible.  
8.2.  Genotoxicity studies 
Genotoxicity test data have been provided (1) for laboratory scale DHC: bacterial mutation assay, in 
vitro chromosome aberration test, in vivo mouse micronucleus test, in vivo Comet assay in rats, (2) 
for commercial grade DHC: gene mutation assay in transgenic rats, in vivo mouse micronucleus test, Safety of dihydrocapsiate 
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and (3) for CH-19 sweet extract: bacterial mutation assay, in vitro chromosome aberration test, in vivo 
mouse micronucleus test.  
The CH-19 sweet extract contained low levels of capsinoids (7.5 % capsinoids of which 20 % is 
DHC);  the results from these tests, albeit all negative, are not considered relevant for the safety 
assessment of DHC. The laboratory scale DHC and commercial grade DHC contained high levels of 
DHC: 95.8 % and 94.0 %, respectively, and are considered relevant. 
8.2.1.  Genotoxicity tests on laboratory scale DHC  
A reverse mutation test in bacteria was carried out, in accordance with Japanese guidelines of the 
Industrial  Safety  and  Health  Law  (Shimada,  2006;  Bernard  et  al.,  2008b).  Four  Salmonella 
typhimurium  strains  (TA98,  TA100,  TA1535  and  TA1537)  and  one  Escherichia  coli  strain 
(WP2uvrA) were used with and without metabolic activation (S9 mix). The results showed some 
evidence for an increase in revertant colonies in TA 100 cells treated in the absence of S9 mix at dose 
levels above 100 μg/plate. There was no evidence for an effect in the DHC-treated plates tested with 
S9 mix. In the definitive assays, up to 1000 and 2500 μg/plate were tested without and with S9 mix, 
respectively. In TA100 without S9 mix, where there was a dose-dependent two-fold or more increase 
in the number of revertant colonies as compared to control, no mutagenic activity was observed with 
or without metabolic activation for any of the other tested strains. The Panel considers that DHC was 
positive in strain TA 100 in the absence of S9 mix. 
An in vitro chromosome aberration assay was carried out in accordance with the Japanese guidelines 
of the Industrial Safety and Health Law (Masumori,  2006; Bernard et al., 2008). Chinese hamster 
lung fibroblasts (CHL/IU cells) were tested with and without metabolic activation (S9 mix). The test 
substance was diluted in dimethylsulfoxide (DMSO). Doses up to 324 μg/ml were tested without S9 
mix and continuous treatment. Up to 1500 μg/ml was tested for short term exposures with S9 mix. 
Doses above 194 μg/ml in the without S9 mix short and long term studies could not be used for 
metaphase analysis due to evident cytotoxicity and the lack of metaphase cells. Mitotic cells were 
scored at 3 dose levels as follows: 70.0, 117 and 194 μg/mL for the short-term treatment without S9 
mix, 540, 900 and 1500 μg/ml for the short-term treatment with S9 mix, and 70.0, 117 and 194 μg/ml 
for the 24-hour continuous treatment without S9 mix. In the short-term treatment with S9 mix, the 
incidence of cells with chromosome aberrations (structural aberrations and numerical aberrations) 
was less than 5%, i.e. chromosome aberrations were not induced. In the short-term assay without S9 
mix,  an  incidence  of  cells  with  chromosome  aberrations  (structural  aberrations  and  numerical 
aberrations) was observed at 194 μg/ml with figures of 9.0 % and 8.0 %. In this treatment, dose 
dependent decreases in relative cell growth were seen, and the relative growth rate was only 38.6% at 
194 μg/ml, which was the highest dose used in the evaluation due to frank cytotoxicity above. In the 
24-hour  continuous  treatment  without  S9  mix,  an  increased  incidence  of  cells  with  chromosome 
structural aberrations occurred at 194 μg/ml, where there was again a significant reduction in relative 
cell growth rate. As the change at the high dose was more than 10%, this test result was judged 
positive.  This  positive  response  was  confirmed  for  the  short-term  and  the  continuous  treatment 
without S9 mix at dose levels of 96.0, 137 and 196 μg/ml in each treatment. Under the condition of 
this assay, the Panel considers that DHC is clastogenic in the absence of metabolic activation. 
An in vivo micronucleus study was carried out according to Ordinance No. 21 (March 26, 1997) on 
standards for conduct of non-clinical studies on safety of drugs, the Ministry of Health and Welfare, 
Japan  (Nakajima,  2006;  Bernard  et  al.,  2008b).  The  assay  was  performed  on  male  BDF1  mice 
(C57BL/6 x DBA/2) aged 9 weeks. Five animals per group were used. The test substance (DHC 
95.8% pure) was diluted in MCT. The test substance was administered by gavage (0.5 ml/100g bw) at 
doses of 500, 1000 and 2000 mg/kg bw for 2 consecutive days. No significant decrease in the ratio of 
polychromatic erythrocytes (PCE) to the total number of analyzed erythrocytes was noted in any of 
the  treatment  groups.  No  statistically  significant  increase  in  the  incidence  of  micronucleated Safety of dihydrocapsiate 
 
EFSA Journal 2012;10(7):2812  17 
polychromatic erythrocytes (MNPCE) was noted in any of the treatment groups compared with the 
negative control. The Panel considers that under the conditions of this in vivo assay in mice, DHC 
was non-clastogenic. 
An in vivo Comet assay in rats (Shimada, 2007; Bernard et al., 2008b) was carried out according to 
methodology described by Tice et al. (2003) and Hartmann et al. (2003). The assay was performed on 
male rats (Crl:CD(SD) aged 8 weeks. Four animals per group were used. The test substance (DHC 
content:  95.8%)  was  diluted  in  MCT.  The  test  substance  was  administered  daily  by  gavage (0.5 
ml/100g bw) at the doses of 1000 and 2000 mg/kg bw for 2 consecutive days. At the end of treatment, 
the intestinal tract, liver and kidney were selected as the potential organs of absorption, metabolism 
and excretion for DHC. The tissues were taken 3 hours after the second dose. In the liver, in the DHC 
group treated with 2000 mg/kg bw, the increase in the Olive tail moment and the mean % tail DNA 
were slightly increased (1.72 and 1.57 times that of the negative control values, respectively) and was 
statistically significant (p < 0.05 Dunnetts Test); both parameters were within the range of variation of 
the historical control data for the testing facility. In the kidney, for the DHC group treated with 2000 
mg/kg bw, the increase in the Olive tail moment was slightly increased (1.32 times that of the negative 
control value), and was statistically significant (p <0.05). At 1000 mg/kg, the increase in the Olive tail 
moment and the mean % tail DNA were also slightly increased (1.35 and 1.21 times that of  the 
negative control values, respectively), and was statistically significant using Dunnett„s test at p = 
<0.05). For the  duodenum, the mean values in the Olive tail moment and the  % tail DNA were 
statistically significantly (p <0.05) increased at 2000 mg/kg bw being 1.72 times and 1.45 times that 
of negative control values, respectively). In the test groups, the actual values for Olive tail moment 
were lower than the historical data from the testing facility, and the mean values in the % tail DNA 
were  almost  the  same  as  the  historical  data.  Under  the  conditions  of  this  assay,  DHC  showed 
equivocal evidence for DNA damage in rats at levels of 1000 mg/kg bw and 2000 mg/kg bw. The 
applicant argues that this result may have occurred because (1) the test has a high false positive rate 
due to apoptosis-induced DNA fragmentation or necrosis at levels inducing cytotoxicity (Tice et al, 
2000; Olive et al, 1990); (2) the assay is known to be highly variable; (3) the increases fell within the 
historical control values of the testing facility and importantly (4) the increases that were observed 
were quantitatively very small, borderline or not dose-related. The Panel agrees with the applicant that 
the results of this assay are equivocal.  
8.2.2.  Genotoxicity tests on commercial grade DHC 
A gene mutation assay of DHC in transgenic Big BlueTM rats (Nakajima, 2007a; Bernard et al., 
2008b) was carried out according to the recommendation of the WHO-IPCS (2006). The assay was 
performed on male Big Blue
TM rats aged 8 weeks. Five animals per group were dosed by gavage at 
500 and 1000 mg/kg for 28 consecutive days. The test substance (DHC content: 94.0%) was diluted in 
MCT. After 3 days following the final treatment, the duodenum, liver and kidney were removed and 
analyzed for mutant frequency. No statistically significant increase in mutant frequency was observed 
in either the liver, the kidney or the duodenum of any groups. Under the conditions of this study, DHC 
was considered to be not mutagenic. 
An  in  vivo  micronucleus  study  (Nakajima,  2007b;  Watanabe,  2008a)  was  carried  out  on  DHC 
according to Ordinance No.21 (March 26, 1997) on standards for conduct of non-clinical studies on 
safety of drugs, the Ministry of Health and Welfare, Japan. The assay was performed on male BDF1 
mice aged 9 weeks. Five animals per group were used. The test substance (DHCcontent: 94.0%) was 
diluted in MCT. DHC was administered by gavage at doses of 500, 1000 and 2000 mg/kg bw for 2 
days. No significant decrease in the ratio of polychromatic erythrocytes (PCE) to the total number of 
analyzed erythrocytes was noted in any of the treatment groups. No statistically significant increase in 
the  incidence  of  MNPCE  was  noted  in  any  of  the  treatment  groups  compared  with  the negative 
control. The Panel considers that under the conditions of this in vivo assay in mice, DHC was non-
clastogenic. Safety of dihydrocapsiate 
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Summary of genotoxicity tests 
The tests on laboratory scale DHC and commercial grade DHC are relevant for the assessment of 
genotoxic potential. The laboratory scale DHC was positive in vitro in the Ames-test (TA 100) as well 
as in the in vitro chromosomal abberation test; in both tests the positive result was seen only in the 
absence of S9 mix. The applicant argues that the latter indicates the ability for in vivo handling of 
potential genotoxicity of DHC.  
Following these positive in vitro tests results, and in line with the EFSA Opinion on genotoxicity 
testing strategies (EFSA, 2011), appropriate in vivo testing for genotoxicity is recommended. For in 
vivo testing, it is necessary that evidence of target cell exposure be obtained in such studies. The 
Panel considers that the data on ADME (Section 8.1) are indicating the presence of DHC breakdown 
products in the blood stream, and are hence suggestive of exposure of the target tissues in vivo. EFSA 
(2011) also indicates that the Comet assay and the gene mutation assay with transgenic animals may 
be recommended as in vivo follow-up tests. 
Both laboratory scale DHC and commercial grade DHC were negative in micronucleus tests in vivo. 
Laboratory scale DHC was equivocal in the Comet assay, and commercial grade DHC was negative in 
the gene mutation assay in transgenic rats.  
The Panel considers that genotoxic activity of DHC observed in vitro in the presence of S9 mix is not 
expressed in vivo in mouse micronucleus studies with both laboratory scale DHC and commercial 
grade DHC, as well as in a gene mutation assay in transgenic rats with commercial grade DHC. Since 
commercial grade DHC is the product to be marketed the equivocal result of the in vivo Comet assay 
is  considered  less  relevant  for  the  assessment.  Furthermore,  there  are  no  structural  alerts  for 
genotoxicity.   
The Panel concludes that it has no safety concerns regarding genotoxicity.  
8.3.  Acute toxicity  
An  acute  oral  toxicity  study  (Kodama,  2007;  Watanabe  et  al.,  2008a)  in  mice  was  performed 
according to the respective Guideline in „Redbook 2000 Guidance for industry and other stakeholders 
- Toxicological principles for the safety assessment of food ingredients‟. Groups of 5 male and 5 
female ICR mice (Crj:CD-1(ICR)) received the test substance (commercial grade; DHC content: 94.0 
%) diluted in MCT at a dose of 5000 mg/kg bw (limit test). The control group received the vehicle 
alone. There were no deaths but during the two hour post-dose observation period staggering gait, 
prone  position,  decreased  spontaneous  movement,  tremor,  gasping  or  red-brownish  urine  were 
observed in some males and females in the group treated with DHC. These findings were transient 
and, with the exception of red-brownish urine, which was also noted after 6 hours post-dosing, there 
were  no  abnormal  findings  at  later  time  points.  No  differences  in  body  weights  were  observed 
between  the  test  and  control  group,  and  there  were  no  abnormal  gross  pathological  findings  at 
necropsy on day 15 after administration. The oral LD50 in mice was thus higher than 5000 mg/kg bw.    
8.4.  Subchronic toxicity 
A 13-week subchronic oral toxicity study (Mochizuki,  2006; Kodama et al., 2008a) with laboratory 
scale DHC was performed according to the „Guidelines for designation of food additives  and for 
revision of standards for use of food additives‟, Notification No. 29 of the Environmental Health 
Bureau, Ministry of Health and Welfare, Japan (March 22, 1996). A GLP compliance statement was 
not provided. In this study, groups of 10 male and 10 female Sprague Dawley rats (Crl:CD(SD)) 
received the test substance (DHC content: 98.5 %) in MCT daily by gavage at doses of 100, 300 and 
1000 mg/kg bw. The control group received the vehicle alone.  Safety of dihydrocapsiate 
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There were no deaths and no treatment-related clinical signs. No statistically significant differences 
were noted between the test groups and the control group regarding body weight, body weight gain, 
food consumption and water intake (except for a difference in water intake for females of the mid-
dose group at one time point, which was not considered relevant). No abnormalities were detected in 
ophthalmoscopy. Haematology analysis showed no relevant differences between the treatment groups 
and  the  control  group.  Clinical-chemistry  analysis  showed  significantly  higher  plasma  alanine 
aminotransferase (ALT) activity (78 %) and total serum protein (TP) levels (7 %) in high-dose males. 
With regard to the increase in ALT activity, the applicant argued that the effect was solely due to a 
high  value  in  a  single  male  rat  of  the  high-dose  group.  However,  careful  consideration  of  the 
individual data showed that two animals in the control group and one animal in the mid-dose group 
also had exceptionally high activities of specific enzymes (ALT, aspartate aminotransferase (AST) 
and lactate dehydrogenase (LDH)). After removal of these outliers the mean values for ALT activity 
were  22,  20,  23  and  34  IU/L  for  the  control,  low-,  mid-  and  high-dose  group,  respectively 
(corresponding to an increase in high-dose males of approximately 41 % compared with the controls). 
Females at the highest dose level showed higher serum levels of calcium (5 %), TP (8 %) and albumin 
(5  %),  a  lower  γ-globulin  level  (-18  %)  and  a  higher  albumin/globulin  (A/G)  ratio  (9  %). 
Determination  of  organ  weights  at  necropsy  revealed  increased  liver  weights,  both  absolute  and 
relative, in high dose animals of both sexes (absolute weight: 16 % in males, 15 % in females; relative 
weight: 20 % in males, 11 % in females). Histopathological examinations of the liver and other 
selected organs and tissues showed no relevant differences regarding the incidence and severity of 
findings between animals of the high-dose group and animals of the control group.  
The Panel considers that laboratory scale DHC at the highest dose level induced several changes 
which  indicate  an effect on the liver (i.e.  higher ALT activity (males), higher albumin, lower γ-
globulin levels, higher albumin/globulin (A/G) ratio and calcium levels (females), higher total protein 
levels and liver weights (both sexes)). The Panel considers that the mid-dose level, i.e. 300 mg/kg 
bw/day, is the no-observed adverse effect level (NOAEL) in this study. 
Another  13-week  subchronic  oral  toxicity  study  in  rats  (Ohishi,  2007;  Watanabe,  2008b)  was 
performed with commercial scale DHC in accordance with the „Guidelines for designation of food 
additives  and  for  revision  of  standards  for  use  of  food  additives‟,  Notification  No.  29  of  the 
Environmental Health Bureau, Ministry of Health and Welfare, Japan (March 22, 1996).  A GLP 
compliance  statement  was  not  provided.  Groups  of  10  male  and  10  female  Sprague  Dawley 
(Crl:CD(SD)) rats were administered the test substance (DHC content: 94.0 %) diluted in MCT by 
gavage at daily doses of 100, 300 and 1000 mg/kg bw. The control group received the vehicle alone. 
No deaths or clinically relevant findings were noted during the treatment period. Food consumption in 
males of the high-dose group was consistently higher compared with the control group from week 42 
onwards, reaching statistical significance at several time-points. This correlated with slightly, but not 
significantly, higher bodyweights  in males of the high-dose group. High-dose males also showed 
increased water intake approximately from week 11 onwards, which was significant at several time-
points.  Ophthalmoscopy  at  the  end  of  the  treatment  period  did  not  reveal  relevant  changes. 
Haematology  analysis  showed  no  significant  differences  between  the  test  groups  and  the  control 
group. Clinical-chemistry analysis showed a significant increase in the plasma ALT activity in the 
high-dose group in both sexes (36 % in males; 29 % in females). In high-dose males, total serum 
protein  (TP)  levels  were  significantly  increased  and  creatinine  levels  were  decreased.  Urinalysis 
showed an increase in urine volume as well as higher sodium, potassium and chloride concentrations 
in the urine for males of the high-dose group.  
High-dose  males  showed  a  significant  increase  in  absolute  and  relative liver and kidney weights 
(liver: absolute 19 %, relative 18 %; kidney: absolute 15 %, relative 12 %). High-dose females had 
higher  relative  liver  and  kidney  weights  (both  11  %).  There  were  no  relevant  findings  in  the 
histopathological examinations of these organs with the exception of hepatocyte hypertrophy in two 
of the high-dose males (graded minimal in one rat and mild in the other) versus none in all other Safety of dihydrocapsiate 
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groups. Examinations of other selected organs and tissues revealed no histopathological changes; the 
findings were randomly distributed between groups and thus considered incidental or spontaneous.  
The changes observed in the high-dose group indicate an effect of the test material on the liver and 
kidneys. Therefore, the intermediate dose of 300 mg DHC/kg bw/day should be regarded as the no-
observed adverse effect level (NOAEL) in this study. 
The Panel notes that in this study commercial grade DHC at the highest dose level induced in part the 
same  specific  changes  indicating  an  effect  on  the  liver  (i.e.  increased  ALT  activity,  total  serum 
protein level and liver weights) as laboratory scale DHC, which was administered at the same dose 
level in the subchronic study described above. In this study, however, commercial grade DHC induced 
additional changes indicative of an effect on the kidney (i.e. changes in urinalysis parameters and 
higher kidney weights), which were not observed after administration of laboratory scale DHC. On 
request  of  the  Panel  to  provide  an  explanation  for  these  differences,  the  applicant  considered 
differences in the production processes, the purity of the starting materials vanillyl alcohol (V-OH) 
and 8-methylnonanoic acid (MNA), and the specification of the tested materials. However, no cause 
for the observed differences in effects could be identified.      
A 26-week oral toxicity study in rats (Kodama, et al 2008b; Ohishi, 2009) with commercial grade 
DHC  followed  by  a  4-week  recovery  period  was  performed  referring  to  the  „Guidelines  for 
designation of food additives and for revision of standards for use of food additives‟, No. 29 of the 
Environmental Health Bureau, Ministry of Health and Welfare, Japan (March 22, 1996). No GLP 
compliance statement was provided. In this study, groups of 20 male and 20 female Sprague Dawley 
(Crl:CD(SD)) rats were administered the test substance (DHC content: 95.4 %) diluted in MCT daily 
by gavage at doses of 100, 300 and 1000 mg/kg bw/day for 26 weeks. The control group received the 
vehicle alone. Ten animals of each sex formed the recovery group and the respective control group.   
There were no deaths during the treatment period but one high dose male was found moribund and 
killed on day 127. Necropsy showed a cerebellar nodule which, when followed by histopathology, 
was found to be a malignant oligodendroglioma in the cerebrum. This was judged to be a spontaneous 
finding unrelated to treatment. Two high-dose females with subcutaneous masses, one in the neck and 
one in the axilliary region, survived to term. The other animals showed no clinically relevant effects 
during  the  treatment  period.  There  were  no  statistically  significant  differences  in  body  weights 
between the test groups and the control group. Food consumption was higher in high-dose females 
compared to the control group from day 77 of treatment, the difference being statistically significant 
at several time points. Higher food consumption continued throughout the 4-week recovery period. 
Water consumption was higher in the high-dose group (statistically significant only in females at two 
time points) and remained higher in the high-dose females during the recovery period (significant at 
one time point). No abnormalities were identified in ophthalmological examinations.  
Haematology analysis showed several significant differences between single test groups compared 
with the control group, the only notable one being higher mean platelet counts in male animals of the 
high-dose group, which persisted until the end of the recovery period. Regarding clinical-chemistry 
parameters ALT activity and total serum protein (TP) levels were significantly increased in the high-
dose group in both sexes. Activity of ALT was also significantly higher in mid-dose males but the 
difference was less after removal of one outlier with an exceptionally high value. There were some 
shifts in specific serum protein fractions but the A/G ratio was not affected. Total cholesterol and 
phospholipid levels were increased in high-dose animals (significantly only in males, also at the mid 
dose). High-dose animals of both sexes had higher calcium levels, which according to the study report 
might be attributable to the increase in the level of the calcium-binding protein, albumin. At the end 
of the recovery period the only significant differences between the high-dose group and the controls 
were shifts in specific protein fractions and slightly, but not significantly, higher TP levels in both 
sexes. Activity of ALT in females was also still considerably higher compared with the controls (i.e. 
48 vs. 19 IU/L after removal of outliers). Urinalysis after 3 months showed that high-dose males had Safety of dihydrocapsiate 
 
EFSA Journal 2012;10(7):2812  21 
significantly higher urine volume (the water intake was not higher at this time point) compared with 
the controls. Urine volume in high-dose females was slightly, but not significantly, higher (water 
intake  as  well).  After  6  months,  urine  volume  as  well  as  sodium,  potassium  and  chloride 
concentrations in the urine were significantly higher in males (water intake not higher). Also at this 
time point, the pH value of the urine was slightly lower. Females also showed a slightly, but not 
significantly, higher urine volume (and water consumption) after 6 months. In both sexes a tendency 
towards decreased concentrations of ketone bodies was observed after 3 as well as 6 months. At the 
end of the recovery period females had a significantly higher urine volume (and water consumption 
but this was not significant). Also in males, urine volume (and water consumption) was still slightly, 
but not significantly, higher compared with the control group.   
At necropsy after 6 months, absolute and relative liver weights were significantly increased in both 
sexes of the high-dose group. Other differences in the high-dose group concerned either absolute or 
relative weights, i.e. higher relative weights of the salivary gland, heart, spleen and kidneys in males 
and higher absolute weights of the pituitary gland (also significant in the mid-dose group), salivary 
gland,  heart,  lung  and  kidneys  in  females.  After  the  recovery  period,  high-dose  females  had 
significantly  increased  relative  liver  and  pituitary  weights,  and  also  salivary  gland  weights  were 
slightly  higher  (not  significant).  Regarding  absolute  weights,  pituitary  gland,  salivary  gland  and 
adrenal weights were significantly increased in females while liver and kidney weights were slightly 
higher (not significant). Histopathological examinations of the liver revealed a higher incidence of 
periportal hepatocyte hypertrophy compared with the controls in both sexes of the high-dose group (2 
vs. 0 in males; 3 vs. 0 in females). High-dose females showed a higher incidence of tigroid cell foci (7 
vs. 2; 5 and 1 per group were observed at the low- and mid-dose, respectively). Both sexes showed a 
higher incidence of hyaline urinary cast in the kidneys (males: 5 vs. 0; females 4 vs. 2). In females, 
tubular  regeneration  was  increased  in  7  animals  (graded  minimal)  vs.  1  in  the  control  group.  In 
addition, higher incidences of extramedullary haematopoesis in the spleen (18 vs. 14) and glandular 
stomach erosion (6 vs. 3) were observed in females. The incidence of focal acinar cell atrophy in the 
pancreas was higher in males (3 vs. 0). After the recovery period there was still a higher incidence of 
tubular regeneration (3 vs. 0) in female kidneys, and males also showed a difference at that time point 
(7 vs. 4). The presence of hyaline urinary cast in female kidneys was still slightly higher (3 vs. 1). 
Adenocarcinoma (2 vs. 0) and increased incidence of focal and lobular hyperplasia (2 vs. 0) were 
observed  in  females  of  the  high-dose  group  at  the  end  of  the  recovery  period  but  the  observed 
incidences were within the normal range for female rats of this strain and age (historical control data 
were  provided).  There  was  also  one  animal  each  in  the  control  and  the  high-dose  group  with 
mammary adenocarcinoma after the 6 month treatment period.    
In this 26-week oral toxicity study, commercial grade DHC induced similar effects as those observed 
in the 13-week rat study using the respective test material. As in the shorter study, the changes in 
specific parameters, which indicate an effect on the liver and kidneys, occurred only at the highest 
dose level. Furthermore, in this study, slightly higher incidences of histopathological changes in the 
liver and kidneys compared with the controls were identified in the high-dose group, which was not 
the case in the study of shorter duration. The study also showed that not all effects induced by the test 
material were reversed at the end of a 4-week recovery period. Therefore, the Panel is of the opinion 
that the mid-dose level, i.e. 300 mg DHC/kg bw/day, should be regarded as the NOAEL in this study. 
Studies on chronic toxicity/carcinogenicity were not provided. 
8.5.  Reproductive and developmental toxicity  
A  developmental  toxicity  study  (Ikeya,  2007;  Bernard,  2008c)  with  commercial  grade  DHC 
administered  orally  to  rats  was  performed  according  to  the  „Guidelines  for  designation  of  food 
additives  and  for  revision  of  standards  for  use  of  food  additives‟,  Notification  No.  29  of  the 
Environmental Health Bureau, Ministry of Health and Welfare, Japan (March 22, 1996). A GLP Safety of dihydrocapsiate 
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compliance statement was not provided. Groups of 18-20 female Sprague Dawley (Crl:CD(SD)) rats 
received the test substance (DHC content: 94.0 %) diluted in MCT by gavage at doses of 100, 300 and 
1000 mg/kg bw/day. The control group received the vehicle alone. Animals mated at 11 or 12 weeks 
of age were dosed for 11 consecutive days on days 7-17 of gestation. Dams were killed on day 20 of 
gestation.  There were no deaths and no differences between the test groups and the control group 
regarding  general  condition,  body  weight  development  and  food  consumption  of  the  dams.  No 
pathological changes were noted in the macroscopic examination at necropsy. Examination of uteri 
contents revealed no relevant differences in the number of corpora lutea, the number of implantations, 
the implantation index, the index of resorbed/dead foetuses and the sex ratio of live foetuses. No 
external malformations were noted regarding live foetuses and the placentas appeared normal. Body 
weights of male foetuses in the high-dose group were significantly higher than in the control group 
but, according to the study report, within the normal ranges. Visceral and skeletal examinations of the 
foetuses revealed no relevant differences in the incidences of abnormalities and variations between 
the groups. There were no relevant differences regarding the progress of ossification. It is concluded 
that  administration  of  DHC  had  no  adverse  effects  on  pregnant  rats  or  on  foetal  growth  and 
development. Thus, the NOAEL in this study is 1000 mg/kg bw, the highest dose administered.  
In  a  similarly  designed  study  (Matsuoka,  2007;  Bernard  et  al.,  2008c),  which  was  performed 
according  to  the  same  Guideline  (GLP  certificate  not  provided),  commercial  grade  DHC  was 
administered to rabbits. Groups of 22 pregnant New Zealand White rabbits (Kbl:NZW) received the 
test substance (DHC conent: 94.0 %) diluted in MCT by gavage at doses of 100, 300 and 1000 mg/kg 
bw. The control group received the vehicle alone. Animals mated at 16-17 weeks of age were dosed 
for 13 consecutive days on days 6-18 of gestation. The dams were killed on day 28 of gestation.  
Regarding the dams, there were no deaths, clinically relevant effects or abortions. Body weights and 
body weight gains in the test groups did not differ significantly from the control group and food 
consumption was comparable in all groups. At necropsy, no relevant gross pathological findings were 
noted. Examination of uteri contents revealed no significant differences in the number of corpora 
lutea, the number of implantations, the implantation index and the index of resorbed/dead foetuses.  
No external malformations were noted regarding live foetuses and the placentas appeared normal. 
There were no differences in sex ratio and foetal body weights between the test groups and the control 
group.  No  relevant  differences  in  the  incidence  of  visceral  and  skeletal  abnormalities,  and  in 
variations in foetuses, were identified between the groups. There were also no relevant differences 
regarding the progress of ossification. It is thus concluded that administration of DHC had no adverse 
effects on pregnant rats or foetal growth and development. The highest dose administered, i.e. 1000 
mg/kg bw/day, is regarded as the NOAEL in this study. 
Studies on reproductive toxicity with DHC were not provided. 
8.6.  Human studies 
A placebo-controlled, randomised, double-blind study with parallel design was performed with 34 
healthy male Japanese subjects (age 30-65 years). In this study, DHC was administered in capsule 
form at doses of 3 or 12 mg/day for 8 days (Kajimoto, 2009a). The control group received the placebo 
(vehicle  only;  rapeseed  oil).  On  the  first  and  last  day  of  the  study  the  participants  completed  a 
questionnaire with regard to the experience of symptoms, and blood samples were taken for clinical-
chemistry and haematology examinations.  The administration of DHC was well-tolerated and none of 
the subjects discontinued dosing due to subjective symptoms or adverse events. The overall incidence 
of subjective symptoms and abnormal laboratory data was similar in the placebo group (3/11), DHC 
low-dose group (1/12) and high-dose group (2/12). Symptoms were recorded in 5 subjects, and the 
reported findings included general malaise (n=1), cough and nasal discharge (n=1), and sore throat 
(n=1) in the placebo group,  constipation as well as bradycardia, pallor, cold sweat and blood pressure 
fall (n=1) in the low-dose group and stiff shoulders (n=1) in the high-dose group. One additional Safety of dihydrocapsiate 
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subject in the high-dose group showed higher cholesterol and blood urea nitrogen (BUN) levels at the 
end of the treatment period. Regarding clinical-chemistry and haematology analyses, as well as blood 
pressure measurements, there were no clinically relevant differences between the placebo and DHC 
groups at baseline (pre-treatment) or at the end of the treatment period. There were also no clinically 
relevant differences between the baseline and final situation in each group.  
In a placebo-controlled, randomised, double-blind study with parallel design including 70 healthy 
male Japanese subjects (age 20-59 years), DHC was administered in beverages at doses of 3 mg/day 
(n=23) or 9 mg/day (n=23) for 4 weeks (Kajimoto, 2009b). The control group (n=24) received a 
placebo (beverage without DHC). On the first and last day of the treatment period the participants 
completed a questionnaire with regard to the experience of symptoms, and blood samples were taken 
for clinical-chemistry and haematology examinations. DHC was well-tolerated in this study and none 
of  the  subjects  discontinued  dosing  due  to  adverse  events.  The  overall  incidence  of  subjective 
symptoms was similar in the placebo group (4/24), the DHC low-dose group (2/23) and DHC high-
dose group (3/23). The most common findings were headache (n=1 in the placebo group and n=2 in 
the high-dose DHC group) and rhinitis (n=1, high-dose). Other signs included heartburn (n=1, high-
dose),  sore  throat  (n=1,  low-dose),  loose  stool  (n=1,  low-dose),  dermatitis  (n=1  placebo),  atopic 
dermatitis  (n=1  placebo)  and  a  decrease  in  body  weight  (n=1,  placebo).  There  were  statistically 
significant differences between day 0 (pre-treatment, baseline) and day 28 (post-treatment) in several 
clinical-chemistry  and  haematology  parameters  in  all  groups,  and  there  were  some  statistically 
significant differences between the placebo and DHC groups on day 0 as well as on day 28. However, 
the variations were assessed to be of no clinical relevance since the changes were within the normal 
range of biological variation. Also, no clinically relevant changes in blood pressure were noted.   
In conclusion, administration of 3 mg or 9 mg DHC/day administered in a beverage over 4 weeks was 
found to be well tolerated. The dosages equated to approximately 0.05 mg/kg bw/day and 0.15 mg/kg 
bw/day based on a bodyweight of 60 kg.  
The Panel is of the opinion that the human studies are of little relevance for the safety assessment 
since  they  were  of  short  duration,  the  administered  doses  were  low,  and  the  number  of  safety 
endpoints studied was limited.  
Interaction with human vanilloid type-1 (TRPV-1) receptors 
Capsaicin exerts its pharmacological effects through the capsaicin receptor, known as the vanilloid 
receptor (VR1) or transient receptor potential vanilloid subfamily member (TRPV1). TRPV1 is a non-
selective cation channel activated by a wide range of  physical and chemical stimuli. Similarly to 
capsaicin,  capsinoids  can  activate  TRPV1  (Luo  et  al.,  2011).  Dihydrocapsiate,  capsiate  and 
nordihydrocapsiate bound to TRPV1 receptors expressed in cultured cells activated Ca2+ influx in a 
concentration-dependent  manner  with  similar  magnitudes;  the  potency  of  the  capsinoids  was 
approximately 1/10 that of capsaicin (Sasahara et al., 2010).  
Pharmacokinetic  studies  in  rats  (Bernard  et  al.,  2010),  as  well  as  the  results  of  a  human  study 
(Bernard  et  al.,  2008),  suggest  that  DHC  is  hydrolysed,  followed  by  rapid  absorption  of  the 
metabolites,  conversion  into  conjugates  and  excretion.  In  contrast  to  the  more  stable  capsaicin, 
dihydrocapsiate is not expected to enter into the systemic circulation in intact form. Effects, such as 
the activation of the sympathetic nervous system (Hachiya et al., 2007), are considered to be due to 
the activation of TRPV1 expressed on the GI tract surface.  
There are no data indicating that the hydrolysis products vanillyl alcohol and 8-methyl-nonanoic acid 
show specific interactions with TRPV-1 receptors. 
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No allergenic reactions have been reported in workers involved in the production of DHC or CH-19 
Sweet extract which is marketed as a food supplement in Japan since 2006 and in the USA since 
2007. 
As dihydrocapsiate is synthesised and not extracted from plant material it is unlikely to cause IgE 
food related allergy. The only potential source of protein entering the production process would be 
from the lipase enzyme in the esterification reaction. The enzyme is immobilised in an inert carrier 
and cannot partition into the n-hexane fraction containing DHC. In the worst case scenario, even if 
granulate “fines” containing the immobilised enzyme entered the hexane layer, the particles would be 
trapped during filtration (filter porosity is 5 μm) and would be separated from the DHC product. The 
applicant  states  that  the  enzyme  manufacturer  (Novozymes,  Denmark)  has  conducted  studies  to 
illustrate that the carrier is robust under normal usage, and that there is no release of the enzyme or 
other materials.   
Although no studies on allergenicity were provided by the applicant, the Panel considers that it is 
unlikely that the novel ingredient poses an allergenic risk. 
DISCUSSION 
Considering the proposed uses the estimated mean intake of synthetic DHC was estimated to be 
around 12 – 13 mg/day (8.1 mg/day for pre-school children); the 97.5
th percentile intakes of adults and 
the elderly were estimated to be around 34 mg/day (18.5 mg/day for pre-school children) based on UK 
consumption data. Calculations based on body weights resulted in the highest intakes being for pre-
school children (mean: 0.6 mg/kg bw/day; 97.5
th percentile: 1.3 mg/kg bw/day).  
The  available  data  on  absorption,  distribution,  metabolism  and  excretion  (ADME)  suggest  that 
ingested DHC is rapidly metabolised in the gut of rats and humans to form vanillyl alcohol, vanillic 
acid and 8-methylnonanoic acid. After absorption the first two are converted into glucuronide and/or 
sulphate conjugates in the liver, and eliminated predominantly by the kidneys into the urine. Total 
excretion in the urine, faeces and expired air after 72 hr was 98.0 %. The methyl-branched fatty acid 
8-methylnonanoic acid is likely to be subject to degradation via ß-oxidation. Terminal ω-oxidation 
might constitute an alternative pathway.  
The applicant has provided a range of toxicological studies with DHC, including in vitro and in vivo 
genotoxicity studies. Based on the results of these studies and in the absence of structural alerts for 
genotoxicity, the EFSA NDA Panel concludes that it has no safety concerns regarding genotoxicity. 
Studies on developmental toxicity in rats and rabbits using commercial grade DHC did not show 
adverse effects on pregnant animals or on foetal growth and development up to the highest dose 
administered (1000 mg/kg bw/day). In a 13-week oral toxicity study in rats with laboratory scale 
DHC, several changes were observed at the highest dose level (1000 mg/kg bw/day) which indicate an 
effect on the liver. Administration of commercial grade DHC to rats for 13 weeks at the same dose 
level  induced  in  part  the  same  specific  changes  indicating  an  effect  on  the  liver.  In  addition, 
commercial  grade  DHC  induced  additional  changes  indicative  of  an  effect  on  the  kidneys.  No 
explanation for the observed differences could be provided by the applicant. The Panel concludes that 
the intermediate dose of 300 mg DHC/kg bw/day is the NOAEL in these 13-week studies. In a 26-
week  oral  toxicity study, commercial grade DHC induced at the highest dose level (1000 mg/kg 
bw/day) similar changes regarding liver- and kidney-specific parameters to those observed in the 13-
week study with commercial grade DHC. Furthermore, slightly higher incidences of histopathological 
changes in the liver and kidneys compared with the controls were identified in the high-dose group. 
Not all effects induced by the test material were reversed at the end of a 4-week recovery period. The 
Panel concludes that 300 mg DHC/kg bw/day is the NOAEL in this study. Safety of dihydrocapsiate 
 
EFSA Journal 2012;10(7):2812  25 
Taking account of the estimated intake levels resulting from the uses as proposed by the applicant, the 
Panel is of the opinion that the margin of safety in relation to the NOAEL of 300 mg/kg bw/day in the 
26-week rat toxicity study is sufficient, including the highest estimated intake of 1.3 mg/kg bw/day for 
preschool children.   
CONCLUSIONS 
The Panel concludes that the novel food ingredient, DHC, is safe under the proposed uses and use 
levels. 
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5. Response by the applicant to the initial assessment report and the Member States' comments and 
objections. 
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